Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04721717 · ClinicalTrials.gov registry record
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
A clinical trial of Multiple Sclerosis and Spinal Cord Injuries, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 160
- Enrollment target
- 1
- Study location
NCT04721717: Recruiting study of Multiple Sclerosis and Spinal Cord Injuries, sponsored by University of Alabama at Birmingham.
NCT04721717 is a study of Multiple Sclerosis and Spinal Cord Injuries that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 160 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04721717, a study of Multiple Sclerosis and Spinal Cord Injuries, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The UAB Institute for Arts In Medicine (AIM) is currently implementing an expressive emotional writing pilot project for adults with paralysis caused by neurological conditions such as traumatic head or spinal cord injury.
Primary Outcome
(Kalpakjian et al., 2015) is a 9-item measure of an individual's emotional reactions or grief such as anger, guilt, anxiety, sadness, and despair in the past 7 days, using a 5-point scale (1=never) to 5 (always). The scores range from 9 to 45. Higher scores reflect higher degree of grief and loss.
Conditions Studied
Study Locations (1)
Alabama
- 354 School of Health Professions Building - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2027-03-28 |
What NCT04721717 shows while recruiting
NCT04721717 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (73% lower).
The record links to 4 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT04721717 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT04721717 about?
NCT04721717 is a clinical study titled "AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis". The UAB Institute for Arts In Medicine (AIM) is currently implementing an expressive emotional writing pilot project for adults with paralysis caused by neurological conditions such as traumatic head or spinal cord injury.
What is the current status of trial NCT04721717?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2020-09-01. Estimated completion is 2027-03-28.
What conditions does trial NCT04721717 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Transverse Myelitis.
Who is sponsoring clinical trial NCT04721717?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04721717 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04721717's enrollment target sits among peer trials
160 89th of 315 higher than 226 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI